ORGANIC
LETTERS
2008
Vol. 10, No. 2
285-288
A Metathesis-Based Approach to the
Synthesis of 2-Pyridones and Pyridines
Timothy J. Donohoe,*,† Lisa P. Fishlock,† and Panayiotis A. Procopiou‡
Department of Chemistry, Chemistry Research Laboratory, UniVersity of Oxford,
Mansfield Road, Oxford, OX1 3TA, United Kingdom, and GlaxoSmithKline Research
& DeVelopment Limited, Medicines Research Centre, Gunnels Wood Road, SteVenage,
Hertfordshire, SG1 2NY, United Kingdom
Received November 5, 2007
ABSTRACT
The ring-closing metathesis reaction has been successfully employed to form a range of dihydropyridone intermediates, which are in the
correct oxidation state to undergo a base-induced elimination to reveal the aromatic 2-pyridone. This mild and novel approach to six-membered
heteroaromatic compounds then provides access to a wide variety of substituted pyridines in excellent overall yield.
The ring-closing metathesis (RCM) reaction has been utilized
extensively throughout the literature to gain access to five-
and six-membered rings;1 however, the application of this
powerful reaction to the formation of aromatic heterocycles
has only recently been highlighted.2
In the case of six-membered heteroaromatics, metathesis-
based approaches are rare and have predominantly involved
oxidation of the RCM product to form the fully aromatic
substrate. For example, Bennasar and co-workers have
established a synthesis of quinolines using an enamide-ene
RCM to form a 1,4-dihydroquinoline, with a subsequent
oxidation catalyzed by Pd/C to provide the corresponding
quinoline.3 O’Brien et al. and Nan et al. have also employed
this RCM/oxidation strategy to construct the 2-pyridone core
in the context of natural product synthesis and library
construction, respectively.4
The aim of this work was to establish a new method of
assembling pyridines based upon RCM as the key C-C
bond-forming reaction. The importance of this aromatic
heterocycle in medicinal chemistry is evident,5 and our
goal was to design a route that would allow the introduc-
tion of a variety of functional groups at any position on the
ring.
† University of Oxford.
‡ GlaxoSmithKline Research & Development Limited.
(1) (a) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem., Int.
Ed. 2005, 44, 4490. (b) Fu¨rstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012.
(c) Armstrong, S. K. J. Chem. Soc., Perkin Trans. 1 1998, 371.
(2) (a) Donohoe, T. J.; Fishlock, L. P.; Lacy, A. R.; Procopiou, P. A.
Org. Lett. 2007, 9, 953. (b) De Matteis, V.; Dufay, O.; Waalboer, D. C. J.;
van Delft, F. L.; Tiebes, J.; Rutjes, F. P. J. T. Eur. J. Org. Chem. 2007,
2667. (c) Donohoe, T. J.; Orr, A. J.; Bingham, M. Angew. Chem., Int. Ed.
2006, 45, 2664. (d) Yoshida, K.; Kawagoe, F.; Iwadate, N.; Takahashi, H.;
Imamoto, T. Chem. Asian J. 2006, 1, 611. (e) Donohoe, T. J.; Orr, A. J.;
Gosby, K.; Bingham, M. Eur. J. Org. Chem. 2005, 1969. (f) Yoshida, K.;
Imamoto, T. J. Am. Chem. Soc. 2005, 127, 10470. (g) Bajracharya, G. B.;
Nakamura, I.; Yamamoto, Y. J. Org. Chem. 2005, 70, 892. (h) Dieltiens,
N.; Stevens, C. V.; Allaert, B.; Verpoort, F. ARKIVOC 2005, 92. (i)
Declerck, V.; Ribie`re, P.; Martinez, J.; Latamy, F. J. Org. Chem. 2004, 69,
8372. (j) Iuliano, A.; Piccioli, P.; Fabbri, D. Org. Lett. 2004, 6, 3711. (k)
Dieltiens, N.; Stevens, C. V.; De Vos, D.; Allaert, B.; Drozdzak, R.;
Verpoort, F. Tetrahedron Lett. 2004, 45, 8995. (l) van Otterlo, W. A. L.;
Ngidi, E. L.; Coyanis, E. M.; de Koning, C. B. Tetrahedron Lett. 2003, 44,
311.
The plan was to develop a rapid route to the pyridine
nucleus via the 2-pyridone core 1; this motif could be
accessed by constructing a dihydropyridone 2 in which a
suitable leaving group is placed on nitrogen (Figure 1). This
(3) (a) Bennasar, M. L.; Roca, T.; Monerris, M.; Garc´ıa-D´ıaz, D.
Tetrahedron Lett. 2005, 46, 4035. (b) Arisawa, M.; Theeraladanon, C.;
Nishida, A.; Nakagawa, M. Tetrahedron Lett. 2001, 42, 8029.
(4) (a) Stead, D.; O’Brien, P.; Sanderson, A. J. Org. Lett. 2005, 7, 4459.
(b) Chen, Y.; Zhang, H.; Nan. F. J. Comb. Chem. 2004, 6, 684.
(5) For recent pharmaceutical targets containing pyridines, see: (a)
Cosford, N. D. P.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.;
Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I.; Rao, S.;
Washburn, M.; Varney, M. A. J. Med. Chem. 2003, 46, 204. (b) Nettekoven,
M. Synlett 2001, 12, 1917.
10.1021/ol702684d CCC: $40.75
© 2008 American Chemical Society
Published on Web 12/23/2007